Synonym
SB 201146; SB201146; SB-201146.
IUPAC/Chemical Name
3-(6-(((3-Aminophenyl)sulfinyl)methyl)-3-((8-(4-methoxyphenyl)octyl)oxy)pyridin-2-yl)acrylic acid lithium salt
InChi Key
RVRATNAADXHAQO-ZJSKVYKZSA-M
InChi Code
InChI=1S/C30H36N2O5S.Li/c1-36-26-15-12-23(13-16-26)9-6-4-2-3-5-7-20-37-29-18-14-25(32-28(29)17-19-30(33)34)22-38(35)27-11-8-10-24(31)21-27;/h8,10-19,21H,2-7,9,20,22,31H2,1H3,(H,33,34);/q;+1/p-1/b19-17+;
SMILES Code
O=C([O-])/C=C/C1=NC(CS(C2=CC=CC(N)=C2)=O)=CC=C1OCCCCCCCCC3=CC=C(OC)C=C3.[Li+]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
542.62
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Beeh KM, Kornmann O, Buhl R, Culpitt SV, Giembycz MA, Barnes PJ. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest. 2003 Apr;123(4):1240-7. PubMed PMID: 12684317.
2: Lee E, Robertson T, Smith J, Kilfeather S. Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med. 2000 Jun;161(6):1881-6. PubMed PMID: 10852761.
3: Lee E, Lindo T, Jackson N, Meng-Choong L, Reynolds P, Hill A, Haswell M, Jackson S, Kilfeather S. Reversal of human neutrophil survival by leukotriene B(4) receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors. Am J Respir Crit Care Med. 1999 Dec;160(6):2079-85. PubMed PMID: 10588632.
4: Salmon M, Walsh DA, Huang TJ, Barnes PJ, Leonard TB, Hay DW, Chung KF. Involvement of cysteinyl leukotrienes in airway smooth muscle cell DNA synthesis after repeated allergen exposure in sensitized Brown Norway rats. Br J Pharmacol. 1999 Jul;127(5):1151-8. PubMed PMID: 10455261; PubMed Central PMCID: PMC1566132.
5: Daines RA, Chambers PA, Foley JJ, Griswold DE, Kingsbury WD, Martin LD, Schmidt DB, Sham KK, Sarau HM. (E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist with oral antiinflammatory activity. J Med Chem. 1996 Sep 13;39(19):3837-41. PubMed PMID: 8809171.
6: Daines RA, Chambers PA, Pendrak I, Jakas DR, Sarau HM, Foley JJ, Schmidt DB, Kingsbury WD. Trisubstituted pyridine leukotriene B4 receptor antagonists: synthesis and structure-activity relationships. J Med Chem. 1993 Oct 29;36(22):3321-32. PubMed PMID: 8230122.
